Abstract
OBJECTIVE—To estimate the fall in coronary heart disease (CHD) mortality in Scotland attributable to medical and surgical treatments, and risk factor changes, between 1975 and 1994. DESIGN—A cohort model combining effectiveness data from meta-analyses with information on treatment uptake in all patient categories in Scotland. SETTING AND PATIENTS—The whole Scottish population of 5.1 million, including all patients with recognised CHD. INTERVENTIONS—All cardiological, medical, and surgical treatments, and all risk factor changes between 1975 and 1994. Data were obtained from epidemiological surveys, routine National Health Service sources, and local audits. MAIN OUTCOME MEASURES—Deaths from CHD in 1975 and 1994. RESULTS—There were 15 234 deaths from CHD in 1994, 6205 fewer deaths than expected if there had been no decline from 1975 mortality rates. In 1994, the total number of deaths prevented or postponed by all treatments and risk factor reductions was estimated at 6747 (minimum 4790, maximum 10 695). Forty per cent of this benefit was attributed to treatments (initial treatments for acute myocardial infarction 10%, treatments for hypertension 9%, for secondary prevention 8%, for heart failure 8%, aspirin for angina 2%, coronary artery bypass grafting surgery 2%, and angioplasty 0.1%). Fifty one per cent of the reduction in deaths was attributed to measurable risk factor reductions (smoking 36%, cholesterol 6%, secular fall in blood pressure 6%, and changes in deprivation 3%). Other, unquantified factors apparently accounted for the remaining 9%. These proportions remained relatively consistent across a wide range of assumptions and estimates in a sensitivity analysis. CONCLUSIONS—Medical treatments and risk factor changes apparently prevented or postponed about 6750 coronary deaths in Scotland in 1994. Modest gains from individual treatments produced a large cumulative survival benefit. Reductions in major risk factors explained about half the fall in coronary mortality, emphasising the importance and future potential of prevention strategies. Keywords: mortality; coronary heart disease; treatment; risk factors
Full Text
The Full Text of this article is available as a PDF (131.7 KB).
Figure 1 .
Sensitivity analysis: best, minimum, and maximum estimate of the contribution of specific treatments and risk factor changes to the coronary mortality fall in Scotland, 1975 to 1994.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beaglehole R. Medical management and the decline in mortality from coronary heart disease. Br Med J (Clin Res Ed) 1986 Jan 4;292(6512):33–35. doi: 10.1136/bmj.292.6512.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bots M. L., Grobbee D. E. Decline of coronary heart disease mortality in The Netherlands from 1978 to 1985: contribution of medical care and changes over time in presence of major cardiovascular risk factors. J Cardiovasc Risk. 1996 Jun;3(3):271–276. [PubMed] [Google Scholar]
- Bowker T. J., Clayton T. C., Ingham J., McLennan N. R., Hobson H. L., Pyke S. D., Schofield B., Wood D. A. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart. 1996 Apr;75(4):334–342. doi: 10.1136/hrt.75.4.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Briggs A., Sculpher M., Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994 Mar-Apr;3(2):95–104. doi: 10.1002/hec.4730030206. [DOI] [PubMed] [Google Scholar]
- Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 8;308(6921):81–106. [PMC free article] [PubMed] [Google Scholar]
- Collins R., Baigent C., Peto R. Benefit of heparin plus aspirin vs aspirin alone in unstable angina. JAMA. 1996 Dec 18;276(23):1873–1874. doi: 10.1001/jama.276.23.1873c. [DOI] [PubMed] [Google Scholar]
- Collins R., Peto R., MacMahon S., Hebert P., Fiebach N. H., Eberlein K. A., Godwin J., Qizilbash N., Taylor J. O., Hennekens C. H. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827–838. doi: 10.1016/0140-6736(90)90944-z. [DOI] [PubMed] [Google Scholar]
- Dobson A., Filipiak B., Kuulasmaa K., Beaglehole R., Stewart A., Hobbs M., Parsons R., Keil U., Greiser E., Korhonen H. Relations of changes in coronary disease rates and changes in risk factor levels: methodological issues and a practical example. Am J Epidemiol. 1996 May 15;143(10):1025–1034. doi: 10.1093/oxfordjournals.aje.a008666. [DOI] [PubMed] [Google Scholar]
- Doliszny K. M., Luepker R. V., Burke G. L., Pryor D. B., Blackburn H. Estimated contribution of coronary artery bypass graft surgery to the decline in coronary heart disease mortality: the Minnesota Heart Survey. J Am Coll Cardiol. 1994 Jul;24(1):95–103. doi: 10.1016/0735-1097(94)90547-9. [DOI] [PubMed] [Google Scholar]
- Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995 May 10;273(18):1450–1456. [PubMed] [Google Scholar]
- Goldman L., Cook E. F. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med. 1984 Dec;101(6):825–836. doi: 10.7326/0003-4819-101-6-825. [DOI] [PubMed] [Google Scholar]
- Hunink M. G., Goldman L., Tosteson A. N., Mittleman M. A., Goldman P. A., Williams L. W., Tsevat J., Weinstein M. C. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA. 1997 Feb 19;277(7):535–542. [PubMed] [Google Scholar]
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994 Feb 5;343(8893):311–322. [PubMed] [Google Scholar]
- Isles C. G., Hole D. J., Hawthorne V. M., Lever A. F. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet. 1992 Mar 21;339(8795):702–706. doi: 10.1016/0140-6736(92)90599-x. [DOI] [PubMed] [Google Scholar]
- Latini R., Maggioni A. P., Flather M., Sleight P., Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995 Nov 15;92(10):3132–3137. doi: 10.1161/01.cir.92.10.3132. [DOI] [PubMed] [Google Scholar]
- Lau J., Antman E. M., Jimenez-Silva J., Kupelnick B., Mosteller F., Chalmers T. C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992 Jul 23;327(4):248–254. doi: 10.1056/NEJM199207233270406. [DOI] [PubMed] [Google Scholar]
- Law M. R., Wald N. J., Thompson S. G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367–372. doi: 10.1136/bmj.308.6925.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mant J., Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ. 1995 Sep 23;311(7008):793–796. doi: 10.1136/bmj.311.7008.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McDonagh T. A., Morrison C. E., Lawrence A., Ford I., Tunstall-Pedoe H., McMurray J. J., Dargie H. J. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997 Sep 20;350(9081):829–833. doi: 10.1016/S0140-6736(97)03033-X. [DOI] [PubMed] [Google Scholar]
- McGovern P. G., Pankow J. S., Shahar E., Doliszny K. M., Folsom A. R., Blackburn H., Luepker R. V. Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med. 1996 Apr 4;334(14):884–890. doi: 10.1056/NEJM199604043341403. [DOI] [PubMed] [Google Scholar]
- Mullen P. D. Compliance becomes concordance. BMJ. 1997 Mar 8;314(7082):691–692. doi: 10.1136/bmj.314.7082.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pocock S. J., Henderson R. A., Rickards A. F., Hampton J. R., King S. B., 3rd, Hamm C. W., Puel J., Hueb W., Goy J. J., Rodriguez A. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet. 1995 Nov 4;346(8984):1184–1189. doi: 10.1016/s0140-6736(95)92897-9. [DOI] [PubMed] [Google Scholar]
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994 Nov 19;344(8934):1383–1389. [PubMed] [Google Scholar]
- Sigfusson N., Sigvaldason H., Steingrimsdottir L., Gudmundsdottir I. I., Stefansdottir I., Thorsteinsson T., Sigurdsson G. Decline in ischaemic heart disease in Iceland and change in risk factor levels. BMJ. 1991 Jun 8;302(6789):1371–1375. doi: 10.1136/bmj.302.6789.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith W. C., Kenicer M. B., Tunstall-Pedoe H., Clark E. C., Crombie I. K. Prevalence of coronary heart disease in Scotland: Scottish Heart Health Study. Br Heart J. 1990 Nov;64(5):295–298. doi: 10.1136/hrt.64.5.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith W. C., Lee A. J., Crombie I. K., Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. BMJ. 1990 Apr 14;300(6730):981–983. doi: 10.1136/bmj.300.6730.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tunstall-Pedoe H., Bailey L., Chamberlain D. A., Marsden A. K., Ward M. E., Zideman D. A. Survey of 3765 cardiopulmonary resuscitations in British hospitals (the BRESUS Study): methods and overall results. BMJ. 1992 May 23;304(6838):1347–1351. doi: 10.1136/bmj.304.6838.1347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tunstall-Pedoe H., Morrison C., Woodward M., Fitzpatrick B., Watt G. Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991. Presentation, diagnosis, treatment, and 28-day case fatality of 3991 events in men and 1551 events in women. Circulation. 1996 Jun 1;93(11):1981–1992. doi: 10.1161/01.cir.93.11.1981. [DOI] [PubMed] [Google Scholar]
- Vartiainen E., Puska P., Pekkanen J., Tuomilehto J., Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ. 1994 Jul 2;309(6946):23–27. doi: 10.1136/bmj.309.6946.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yusuf S., Zucker D., Peduzzi P., Fisher L. D., Takaro T., Kennedy J. W., Davis K., Killip T., Passamani E., Norris R. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994 Aug 27;344(8922):563–570. doi: 10.1016/s0140-6736(94)91963-1. [DOI] [PubMed] [Google Scholar]